Is the post-earnings rally in this struggling life sciences stock for real this time?
-
最新报道：The struggling life sciences company saw its stock surge over 20% in post-earnings trading, marking its biggest single-day gain this year. While revenue declined 8% year-over-year to $152 million, the firm beat analyst estimates by $3 million and reported narrower-than-expected losses of $0.18 per share versus the projected $0.25. CEO Dr. Sarah Chen highlighted "meaningful progress" in their flagship drug trial, with Phase 2 data showing improved efficacy rates. However, analysts remain cautious as the company's cash reserves dwindled to $89 million, raising concerns about its ability to fund operations beyond Q1 2026 without additional financing. Short interest remains elevated at 32% of float.
下一篇
Bitcoin Futures Market Cools, Setting Stage for BTC Move
- Bitcoin futures are cooling down ? — reduced speculation hints at BTC’s next big move! #Bi...
24小时热点
热点专题
407106